ClinicalTrials.gg
RecruitingNCT06907342COSENSE-1Updated Jul 20, 2026

Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)

A Phase 2 interventional study of FOLFOX or FOLFIRI in Tumor, Colorectal, Organoids and Tumoroid, sponsored by St. Olavs Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by St. Olavs Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Colorectal Neoplasms with a site in Norway — 19 open to participants now, 35 under way, 6 of them phase 3. Colorectal Neoplasms · Norway.

Planned enrollment
39th of 68
148 · median 172
Started
2025
with 3 others
Phase 2
12 of 82
2 open now
Primary completion
2027-12
later than 17 of 34 live
Registered
75th of 82
by date
Lead sponsor
3 of 82
St. Olavs Hospital

Among the 82 studies in Colorectal Neoplasms with a site in Norway, this one is the 39th largest by planned enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 17 of the 34 other live ones, and was the 75th registered.

Colorectal Neoplasms

6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

19 of the 82 studies in Colorectal Neoplasms with a site in Norway are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Colorectal Neoplasms with a site in Norway, or all of them as a file.
02

Study summary

COSENSE-1 is an unblinded, phase II, single-armed, single center feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens, for male and female participants aged 18 and older, with microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC), that is incurable or not resectable with curative intent.

Read the detailed description

Objectives: The primary objective of this study is to test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer. Secondary objectives are to describe the tumour response to treatment using efficacy measures and assess the progression-free survival and the overall survival, and assess the toxicity experienced by the participants. Exploratory objectives include basal research on tumouroids and optimisation of the functional assay to be compatible with clinical practice.

Primary endpoints: The primary endpoints are assessing feasibility:

  1. The rate of generating valid tumouroid response reports (valid is defined as a fold-change growth in untreated controls of > 1, registered on day 5, 6, 7 or 8 and normalised with resepect to day 0 or 1): a) per patient included in the trial and b) per patient with successful tumour sample.
  2. The time from referral to start of allocated treatment.

Secondary endpoints: Secondary endpoints include efficacy in the form of Response Rates (RR) graded and measured using RECIST v1.1, including Objective Response Rate (ORR), Disease Control Rate (DCR) and Clinical Benefit Rate (CBR), as well as Duration of Response (DoR), Progression Free Survival (PFS), Progression Free Survival Rate at 6 months (PFSR) and Overall Survival (OS). Toxicity will be graded using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v.5.0).

Trial design and patient population: COSENSE-1 is an unblinded, phase II, single-armed, single-center, consent-based feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens, for male and female participants aged 18 and older, with microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) that is incurable or not resectable with curative intent. Participants can proceed to the treatment cohort of the trial if standard of care treatment can be allocated within the timeframes given by the Norwegian national recommendations for the treatment of colorectal cancer. The study duration will be up to 36 months for each participant with treatment duration up to 6 months, and the study visit frequency will be one per participant.

Main inclusion criteria:

  • ECOG performance status 0 or 1
  • Acceptable organ function as defined in Section 5.1 "Inclusion criteria"
  • Histologically confirmed pMMR/MSS adenocarcinoma originating from the colon or rectum
  • Unresectable metastatic disease (not amenable to radical surgery of the cancer disease at the time of study inclusion)
  • The oxaliplatin-based regimen FOLFOX (+/- antibody) versus the irinotecan-based regimen FOLFIRI (+/- antibody), are evaluated by an experienced physician, independent of inclusion in the trial, to be equally recommended for the participant as standard of care first-line therapy in the treatment of mCRC, following the Norwegian national guideline on the treatment of colorectal cancer
  • Patient is eligible for full (100%) chemotherapy doses at first treatment cycle

Main exclusion criteria:

  • Patient has metastatic MMR deficient/MSI adenocarcinoma
  • Patient is ineligible for full (100%) chemotherapy doses at first treatment cycle
  • ECOG performance status 2 or worse
  • Inability to understand study procedures and comply with them, or disorder that compromises the patient's ability to provide informed consent and/or comply with study procedures
  • Patient is not equally eligible for FOLFOX (+/- antibody) and FOLFIRI (+/- antibody) chemotherapy regimens, according to the Norwegian national guideline on the treatment of colorectal cancer

Number of participants:

Approximately 148 patients will be screened to achieve:

  1. 133 participants for evaluation of primary and exploratory objectives and endpoints, assessing feasibility.
  2. 73 participants for evaluation of all objectives and endpoints, including secondary objectives and endpoints.

Intervention: Oxaliplatin-based or irinotecan-based chemotherapy regimen based on patient-derived tumouroids as guide for clinical decision.

Ethical considerations:

For over two decades, both type of chemotherapy regimens (oxaliplatin-based and irinotecan-based) have been considered equal first-line treatment regimens for this patient group. In clinical practice as of today, no biomarkers are available to guide whether oxaliplatin-based or irinotecan-based chemotherapy will be most effective in treating the individuals' cancer disease. Therefore, treatment typically begins with either regimen, often influenced by local traditions or practices. Furthermore, effectiveness of the chosen regimen is monitored clinically and radiologically, and if efficacy is insufficient or toxicities are intolerable, patients are switched to the alternative regimen after 2-3 months. These months are significant for patients with already limited life expectancy. The COSENSE-1 trial offers a more rational approach by providing the most promising chemotherapy regimen upfront. The prerequisites for COSENSE-1, discards the risk of being allocated to inferior treatment compared to clinical practice, and assures similar time frames, safety and toxicity profiles as in clinical practice.

03

Conditions studied

  • Tumor, Colorectal
  • Organoids
  • Tumoroid
  • Metastatic Colorectal Cancer
  • Core Needle Biopsy
  • First-line Treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General conditions:

  1. Age 18 or older
  2. performance status 0 or 1
  3. Obtained
  4. Acceptable organ function (defined in publicly available protocol)
  5. Women of and men must agree to use highly effective (defined in publicly available protocol)

    Disease and treatment specific conditions:

  6. confirmed pMMR/MSS adenocarcinoma originating from the colon or rectum
  7. Unresectable disease (not amenable to radical surgery of the cancer disease at the time of study inclusion)
  8. Patient has metastatic or primary lesion available for
  9. Patient has measurable or evaluable disease per (version 1.1)
  10. The oxaliplatin-based regimen FOLFOX (+/- antibody) versus the irinotecan-based regimen FOLFIRI (+/- antibody), are evaluated by an experienced physician, independent of inclusion in the trial, to be equally recommended for the participant as standard of care therapy in the treatment of mCRC, following the Norwegian national guideline on the treatment of colorectal cancer (https://www.helsedirektoratet.no/retningslinjer/kreft-i-tykktarm-og-endetarm-handlingsprogram)
  11. Patient is eligible for full (100%) chemotherapy doses at first treatment cycle
  12. Treatment with chemotherapy can be scheduled within 28 days from referral

Exclusion criteria

Exclusion Criteria:

  1. Patient has MMR deficient/MSI adenocarcinoma
  2. Patient is ineligible for full (100%) chemotherapy doses at first treatment cycle
  3. Patient is not equally eligible for FOLFOX (+/- antibody) and FOLFIRI (+/- antibody) chemotherapy regimens, according to the Norwegian national guideline on the treatment of colorectal cancer
  4. performance status 2 or worse
  5. Pregnancy or planned pregnancy during the study period, due to the risks of drug treatment to a developing foetus
  6. Breastfeeding
  7. Patients with psychological, geographical, familial or sociological conditions that can prevent compliance with the study protocol
  8. Inability to understand study procedures and comply with them, or disorder that compromises the patient's ability to provide and/or comply with study procedures
  9. Patient fulfils any of the listed in the SmPC of the relevant IMP
  10. Treatment cannot be scheduled within 28 days from referral

    Medical history:

  11. Partial or complete dihydropyrimidine dehydrogenase (DPD) deficiency
  12. Evidence of
  13. Unresolved toxicities of a previous systemic treatment that, in the opinion of the physician, make the patient unfit for inclusion
  14. Antitumoural treatment ≤ 30 days before inclusion. Hormonal substitutive treatment is allowed
  15. Preexisting significant cardiovascular disease including uncontrolled/unstable or symptomatic angina, uncontrolled atrial or ventricular arrythmias, known to be \< 40% or symptomatic congestive heart failure
  16. Stroke (including ) or acute myocardial infarction within 6 months before the first dose of study treatment
  17. peripheral sensory neuropathy
  18. Recent (\<6 months before the start of study treatment) pulmonary embolism, deep vein thrombosis, or another significant thromboembolic event
  19. History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on chest computed tomography (CT)
  20. Evidence of previous acute reaction to any component of the treatment
  21. History of any disease that may increase the risks associated with study participation
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Treatment cohort

    FOLFOX or FOLFIRI based on readout from patient-derived tumouroids (via biopsy)

    Drug: FOLFOX or FOLFIRI

Interventions

  • DrugFOLFOX or FOLFIRI

    Treatment allocation from tumouroid readout

06

What researchers measure

Primary outcomes

  1. Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer.

    Rate of generating valid\* tumouroid response reports per patient included in the trial. \*A valid tumouroid response report for a sample is defined as a fold-change growth in untreated controls of \> 1, registered on day 5, 6, 7 or 8 and normalised with respect to day 0 or 1.

    Time frame: Up to 1 month

  2. Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer.

    Rate of generating valid\* tumouroid response reports per patient with obtained tumour sample. \*A valid tumouroid response report for a sample is defined as a fold-change growth in untreated controls of \> 1, registered on day 5, 6, 7 or 8 and normalised with resepect to day 0 or 1.

    Time frame: Up to 1 month

  3. Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer.

    What is the time from referral to start of allocated treatment

    Time frame: Up to 1 month

Secondary outcomes

  1. Describe the tumour response to treatment using RECIST v.1.1

    Objective Response Rate (ORR)

    Time frame: Up to 48 months

  2. Describe the tumour response to treatment using RECIST v.1.1

    Disease Control Rate (DCR)

    Time frame: Up to 48 months

  3. Describe the tumour response to treatment using RECIST v.1.1

    Clinical Benefit Rate (CBR), defined as the percentage of patients who had a complete response, partial response, or had stable disease for 6 months or more

    Time frame: Up to 48 months

  4. Describe the tumour response to treatment using RECIST v.1.1

    Duration of Response (DoR)

    Time frame: Up to 48 months

  5. Assess progression free survival

    Progression Free Survival (PFS), defined as the time from starting first-line treatment to the time of documentation of progressive disease (PD) according to RECIST v.1.1 on active therapy, determined failure of treatment strategy or death

    Time frame: Up to 5 years

  6. Assess progression free survival rate

    Progression Free Survival Rate (PFSR), defined as the ratio of participants with PFS at 6 months

    Time frame: Up to 6 months

  7. Assess overall survival

    Overall Survival

    Time frame: Up to 5 years

  8. Toxicity experienced in the trial

    Incidence of grade 3-5 adverse events using CTCAE v.5.0

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 31 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2025
First posted
Apr 2, 2025
StartActual
May 23, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Sep 2040
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06907342
Lead sponsor
St. Olavs Hospital
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
May 23, 2025
Primary completion
Dec 2027 (estimated)
Completion
Sep 2040 (estimated)
Last update
Jul 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion